Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

The company found that the 1 mg dose of Z-endoxifen reduced MBD by 17.3 percentage points, whereas the 2 mg dose achieved a reduction of 23.5 percentage points. Meanwhile, a minimal change of 0.27 ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Raven-Symoné recently opened up about undergoing surgery at a very young age. In her comments, the actor stated that she did so after receiving advice that a breast reduction procedure would help her ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

Offering access to healthcare benefits that include comprehensive preventative care like breast and heart-health screenings ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

The 38-year-old actress opens up about her first breast reduction and the pressures of the entertainment industry that led to ...

Over the past 45 years, cancer prevention and screening accounted for most cancer deaths averted for breast, cervical ...